The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL).
Tongyu Lin
No relevant relationships to disclose
Jun Zhu
No relevant relationships to disclose
Kamal Bouabdallah
No relevant relationships to disclose
Michinori Ogura
No relevant relationships to disclose
Masayuki Hino
No relevant relationships to disclose
Jin Seok Kim
No relevant relationships to disclose
Cassandra Wu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Claudia Corrado
Employment or Leadership Position - Novartis
Thomas E. Witzig
Consultant or Advisory Role - Celgene; Novartis; Seattle Genetics; Takeda
Honoraria - Avila Therapeutics; Hospira
Research Funding - Novartis